D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Immunology D-index 56 Citations 9,774 154 World Ranking 2113 National Ranking 16

Overview

What is he best known for?

The fields of study he is best known for:

  • Gene
  • Immune system
  • Cancer

Haiming Wei mostly deals with Immunology, Interleukin 21, Interleukin 12, Natural killer T cell and Lymphokine-activated killer cell. His Immunology research is multidisciplinary, incorporating elements of NKG2D, Liver injury and Respiratory system. His Interleukin 21 research is multidisciplinary, incorporating perspectives in Natural killer cell, Innate immune system, Innate lymphoid cell and IL-2 receptor.

His Natural killer cell research includes elements of Endocrinology and Internal medicine. His Interleukin 12 study combines topics from a wide range of disciplines, such as Perforin, Cytotoxicity, Antigen-presenting cell and Cell biology. He has included themes like Cellular differentiation and Cytokine in his Lymphokine-activated killer cell study.

His most cited work include:

  • Effective treatment of severe COVID-19 patients with tocilizumab. (1290 citations)
  • Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients (409 citations)
  • Liver-resident NK cells confer adaptive immunity in skin-contact inflammation. (338 citations)

What are the main themes of his work throughout his whole career to date?

His primary areas of investigation include Immunology, Interleukin 21, Interleukin 12, Cell biology and Cancer research. His study in Immunology is interdisciplinary in nature, drawing from both Natural killer cell and Liver injury. The Interleukin 21 study combines topics in areas such as Innate immune system, IL-2 receptor and Antigen-presenting cell.

Many of his research projects under Interleukin 12 are closely connected to Myeloid-derived Suppressor Cell with Myeloid-derived Suppressor Cell, tying the diverse disciplines of science together. He has researched Cell biology in several fields, including Phenotype, Transcription factor, Receptor, Cell Maturation and Cytolysis. He combines subjects such as Cell, Lung cancer, In vivo and Immunotherapy with his study of Cancer research.

He most often published in these fields:

  • Immunology (54.38%)
  • Interleukin 21 (23.50%)
  • Interleukin 12 (22.58%)

What were the highlights of his more recent work (between 2018-2021)?

  • Immunology (54.38%)
  • Cancer research (21.66%)
  • Tocilizumab (4.61%)

In recent papers he was focusing on the following fields of study:

Haiming Wei mainly focuses on Immunology, Cancer research, Tocilizumab, Immune system and Cell biology. His Immunology study frequently draws connections to other fields, such as Cell. His Cancer research research is multidisciplinary, incorporating elements of Natural killer cell, TIGIT, Immunotherapy and Hepatitis B virus.

Haiming Wei has included themes like Clinical trial, MEDLINE and Monocyte in his Tocilizumab study. His studies in Immune system integrate themes in fields like Interferon and Interleukin 12. He has researched Cell biology in several fields, including Phenotype, Cell Maturation, Transcription factor and Transcription.

Between 2018 and 2021, his most popular works were:

  • Effective treatment of severe COVID-19 patients with tocilizumab. (1290 citations)
  • Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients (409 citations)
  • Why tocilizumab could be an effective treatment for severe COVID-19? (217 citations)

In his most recent research, the most cited papers focused on:

  • Gene
  • Immune system
  • Cancer

His primary areas of study are Immunology, Immune system, Cancer research, Tocilizumab and Cell. Inflammation is the focus of his Immunology research. His research integrates issues of Acquired immune system, Natural killer cell, Hepatitis B virus and TIGIT, Immunotherapy in his study of Cancer research.

His Tocilizumab study integrates concerns from other disciplines, such as CD8 and Monocyte. His Cell research is multidisciplinary, relying on both Cancer, PD-L1, Viral load and Immunity. Haiming Wei interconnects Gastroenterology and Oxygen therapy, Internal medicine, Cytokine in the investigation of issues within Antibody.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Effective treatment of severe COVID-19 patients with tocilizumab.

Xiaoling Xu;Mingfeng Han;Tiantian Li;Wei Sun.
Proceedings of the National Academy of Sciences of the United States of America (2020)

2021 Citations

Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients

Yonggang Zhou;Binqing Fu;Xiaohu Zheng;Dongsheng Wang.
National Science Review (2020)

622 Citations

Liver-resident NK cells confer adaptive immunity in skin-contact inflammation.

Hui Peng;Xiaojun Jiang;Yonglin Chen;Dorothy K. Sojka.
Journal of Clinical Investigation (2013)

385 Citations

Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity.

Qing Zhang;Jiacheng Bi;Jiacheng Bi;Xiaodong Zheng;Yongyan Chen.
Nature Immunology (2018)

326 Citations

Why tocilizumab could be an effective treatment for severe COVID-19?

Binqing Fu;Xiaoling Xu;Haiming Wei.
Journal of Translational Medicine (2020)

322 Citations

Breakdown of adaptive immunotolerance induces hepatocellular carcinoma in HBsAg-tg mice

Lu Zong;Hui Peng;Cheng Sun;Fenglei Li.
Nature Communications (2019)

296 Citations

Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus

Yonggang Zhou;Binqing Fu;Xiaohu Zheng;Dongsheng Wang.
bioRxiv (2020)

244 Citations

Natural Killer Cells Promote Immune Tolerance by Regulating Inflammatory TH17 Cells at the Human Maternal-Fetal Interface

Binqing Fu;Xian Chang Li;Xian Chang Li;Rui Sun;Xianhong Tong.
Proceedings of the National Academy of Sciences of the United States of America (2013)

232 Citations

Respiratory influenza virus infection induces intestinal immune injury via microbiota-mediated Th17 cell–dependent inflammation

Jian Wang;Fengqi Li;Haiming Wei;Zhe-Xiong Lian.
Journal of Experimental Medicine (2014)

229 Citations

TGF-β1 Down-Regulation of NKG2D/DAP10 and 2B4/SAP Expression on Human NK Cells Contributes to HBV Persistence

Cheng Sun;Binqing Fu;Yufeng Gao;Xiaofeng Liao.
PLOS Pathogens (2012)

200 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Haiming Wei

Zhigang Tian

Zhigang Tian

University of Science and Technology of China

Publications: 126

Eric Vivier

Eric Vivier

Aix-Marseille University

Publications: 34

Nicholas D. Huntington

Nicholas D. Huntington

Monash University

Publications: 29

Bin Gao

Bin Gao

National Institutes of Health

Publications: 27

Julio Villena

Julio Villena

National Scientific and Technical Research Council

Publications: 27

M. Eric Gershwin

M. Eric Gershwin

University of California, Davis

Publications: 25

Joseph C. Sun

Joseph C. Sun

Memorial Sloan Kettering Cancer Center

Publications: 21

Antonio Bertoletti

Antonio Bertoletti

Duke NUS Graduate Medical School

Publications: 20

Mengji Lu

Mengji Lu

University of Duisburg-Essen

Publications: 20

Gabrielle T. Belz

Gabrielle T. Belz

University of Queensland

Publications: 19

Nima Rezaei

Nima Rezaei

Tehran University of Medical Sciences

Publications: 19

Svetomir N. Markovic

Svetomir N. Markovic

Mayo Clinic

Publications: 19

Lorenzo Moretta

Lorenzo Moretta

Bambino Gesù Children's Hospital

Publications: 19

Lewis L. Lanier

Lewis L. Lanier

University of California, San Francisco

Publications: 18

Thierry Walzer

Thierry Walzer

Claude Bernard University Lyon 1

Publications: 18

Mark J. Smyth

Mark J. Smyth

QIMR Berghofer Medical Research Institute

Publications: 17

Something went wrong. Please try again later.